Loading
Immunome
Immunome is a US biotechnology company whose lead drug varegacestat, a gamma-secretase inhibitor acquired with Ayala Pharmaceuticals, completed the phase 3 RINGSIDE trial in progressing desmoid tumours; it also develops antibody-drug conjugates.
Also called: Immunome, Inc.Ayala Pharmaceuticals
Overview
Immunome, headquartered in Bothell, Washington, develops targeted cancer therapies. Its most advanced programme is varegacestat (AL102), an oral gamma-secretase inhibitor that blocks Notch signalling and was tested against placebo in the phase 3 RINGSIDE trial in adults and adolescents with progressing desmoid tumours; the programme came with the acquisition of Ayala Pharmaceuticals' assets. The company also develops antibody-drug conjugates from its own antibody discovery platform. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Bothell, WA, US
Scorecard
All companies#443of 1245 companies, score 7
- phase 3 +3
- modalities +2
- registry trials +2
0 approved, 1 in phase 3, 0 earlier, 0 targets, 1 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Products
1Phase 3small molecule
Varegacestat is an experimental small-molecule drug from Immunome in phase 3 trials for desmoid tumour, with its target not yet stated publicly.
Connected
5Similar pages
- TreatmentNirogacestat
Shares Gamma-secretase (PSEN1), Desmoid tumour.
cancers
fronts
targets
drugs
Phase 3small molecule
trials
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
ClinicalTrials.gov · 1
immunome.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/